Paxman

Invitation: Presentation with Richard Paxman – Q3 2026

Källa: MFN
Neutral

Sammanfattning

Paxman kallar till presentation av sin rapport för tredje kvartalet 2026 den 20 november. Presentationen kommer att kommenteras av VD Richard Paxman och hållas på engelska.

Analys

Bolaget publicerar sin rapport för tredje kvartalet 2026 den 20 november. En presentation för investerare, analytiker och media kommer att hållas samma dag kl. 09:00 CET. VD Richard Paxman kommer att kommentera rapporten under presentationen. Frågor kan skickas in i förväg.

VD-ord

Något tydligt VD-ord kunde inte identifieras i rapportunderlaget.

Insikter

  • • Presentation av Q3-rapporten kommer att hållas den 20 november.
  • • VD Richard Paxman kommer att kommentera rapporten.
  • • Presentation och Q&A kommer att ske på engelska.
Fundamental påverkan
Neutral

Ingen direkt fundamental påverkan då detta endast är en inbjudan till en rapportpresentation.

Omfattning: 1/10Marginell påverkan
0 · Ingen påverkan10 · Avgörande påverkan

Poängen visar omfattning, inte förväntad kursrörelse.

PAXMAN will publish its report for the third quarter of 2026 on 20 November. A presentation for investors, analysts and the media will be published on the same day at 9:00 a.m. CET.

PAXMAN will publish its report for the third quarter of 2026 on 20 November. A presentation for investors, analysts and the media will be published on the same day at 9:00 a.m. CET.

During the presentation, CEO Richard Paxman will comment on the report. The Q&A session will be moderated by Maria Karlsson Osipova. The presentation will be held in English.Questions may be submitted in advance to Maria Karlsson Osipova (maria.karlsson.osipova@dnbcarnegie.se) - these questions will be addressed during the presentation. Written questions received on 20 November will be compiled and forwarded to the company, with a written Q&A to be published subsequently.The presentation can be accessed on https://www.youtube.com/@DNBCarnegiePlay at 9:00 a.m. CET on the 20th of November.

Contacts

Richard Paxman, CEO Tel: +44 7968 020641 Email: Richard.Paxman@paxmangroup.comhttps://investor.paxmangroup.com/

About Us

Paxman Group is a global medical technology company focused on improving quality of life for people undergoing chemotherapy through innovative side-effect management solutions. Its portfolio addresses two of the most challenging treatment-related side effects: chemotherapy-induced alopecia (hair loss) and chemotherapy-induced peripheral neuropathy (CIPN).

Paxman Group’s scalp cooling technologies, including the Paxman Scalp Cooling System and the DigniCap Scalp Cooling System, are used globally in hospitals and cancer centres to support patients undergoing chemotherapy by helping to reduce the risk of chemotherapy-induced hair loss. The clinically validated Paxman Neuropathy System supports the prevention of CIPN through cryocompression technology.

Founded through the Paxman family's personal experience of cancer treatment, Paxman Group works with patients, clinicians and research partners to advance side effect management in cancer care globally.

PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden). Subsidiaries of the PAXMAN Group are Paxman Coolers Limited (Huddersfield UK), Paxman Inc. (Houston, Texas US), Paxman Canada (Toronto, Ontario CA), Dignitana AB (Lund, Sweden), Dignitana Inc. (Dallas, TX US), and Dignitana S.r.l. (Milan, IT).

Paxman AB (publ) is listed on Nasdaq First North Growth Market with FNCA Sweden AB as Certified Adviser.

Attachments

Invitation: Presentation with Richard Paxman – Q3 2026

Öppna PDF

Fler nyheter från Paxman

Relaterade pressmeddelanden och bolagshändelser från samma bolag.

Se bolagssidan